#Topcat clinical trial trial

However, there was a trend toward lower HF hospitalization in the spironolactone group (12% vs. There was no difference between the spironolactone and placebo groups for the studyвЂ™s primary composite endpoint of death, aborted cardiac arrest or HF hospitalization.

#Topcat clinical trial trial

The international, multicenter, NHLBI-funded trial included 3,445 patients with HFpEF (mean EF, 56% mean age, 69 years majority NYHA Class II/III) and elevated BNP/NT-proBNP or hospitalization for HF in the last year who were randomly assigned spironolactone or placebo. Pfeffer, MD, PhD, presented results at a late-breaking clinical trial session in Dallas. On behalf of the TOPCAT investigators, Marc A. Clinicians continue to struggle with optimal medical management of these patients, and so results from the recently completed TOPCAT trial were highly anticipated at AHA 2013. One of my favorite questions to ask instead is: What therapies improve mortality in patients with HF with preserved ejection fraction? Unfortunately, this question has stumped medical students and HF specialists alike for many years.ДЄs the population ages and develops predisposing comorbidities, HF with preserved ejection fraction (HFpEF) has become a growing epidemic associated with high prevalence, hospitalization and economic burden.

If you continue to have this issue please contact to HealioДALLAS - A common question in medicine is: What therapies improve mortality in patients with HF with reduced ejection fraction? As a current cardiology fellow, I have вЂњgrown upвЂќ in an era in which medical students and residents are able to rapidly rattle off the many correct answers to this common question on rounds.